Insider Selling: TransMedics Group (NASDAQ:TMDX) Insider Sells $412,629.92 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Nicholas Corcoran sold 2,966 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $412,629.92. Following the completion of the sale, the insider directly owned 29,831 shares in the company, valued at approximately $4,150,088.72. The trade was a 9.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

TransMedics Group Price Performance

TransMedics Group stock opened at $129.80 on Friday. TransMedics Group, Inc. has a 1 year low of $62.23 and a 1 year high of $156.00. The firm has a 50 day moving average price of $135.35 and a 200 day moving average price of $126.90. The company has a market cap of $4.45 billion, a price-to-earnings ratio of 26.49 and a beta of 1.98. The company has a debt-to-equity ratio of 1.06, a quick ratio of 6.59 and a current ratio of 7.14.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TMDX. Amalgamated Bank lifted its holdings in TransMedics Group by 0.8% in the second quarter. Amalgamated Bank now owns 9,586 shares of the company’s stock valued at $1,285,000 after buying an additional 80 shares during the period. D.A. Davidson & CO. grew its holdings in shares of TransMedics Group by 0.5% in the 4th quarter. D.A. Davidson & CO. now owns 15,334 shares of the company’s stock valued at $1,865,000 after buying an additional 83 shares during the period. Parallel Advisors LLC raised its stake in TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after buying an additional 83 shares during the period. Crossmark Global Holdings Inc. lifted its holdings in TransMedics Group by 4.0% during the fourth quarter. Crossmark Global Holdings Inc. now owns 2,275 shares of the company’s stock worth $277,000 after acquiring an additional 88 shares in the last quarter. Finally, HighPoint Advisor Group LLC grew its stake in TransMedics Group by 3.1% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,955 shares of the company’s stock valued at $359,000 after acquiring an additional 88 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

TMDX has been the subject of a number of research analyst reports. Morgan Stanley upped their price objective on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Piper Sandler lifted their target price on TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Oppenheimer boosted their price target on TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. upped their price target on TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 25th. Finally, Needham & Company LLC raised their price objective on TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $150.67.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.